Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2003

View Archived Issues

FluINsure shows positive results in influenza challenge study

Twice-daily schedule suggested for fampridine-SR in patients with chronic SCI

Astex achieves milestone in Alzheimer's drug discovery collaboration

CAT and Genzyme strengthen drug development collaboration

DepoMed acquires exclusive rights to novel gabapentin formulation

Phase IIa study initiated with SPI-8811 for cystic fibrosis

Alnylam enters RNAi-based therapy collaboration with Stanford University

Pivotal trial for Hunter's syndrome begins dosing

New formulation of Singulair available for young children with asthma

FDA grants satraplatin fast track designation

New antiangiogenic agents and their use patented by EntreMed

Takeda presents new GnRH antagonists for cancer, prostatic hypertrophy, etc.

Dainippon scientists prepare and test novel glucagon antagonists

New antifungal agents in early development at Daiichi

Novel agents for urinary incontinence described by Mochida and Asahi Glass

New CDK inhibitors in BMS development pipeline

Phase IIIa study of Neutralase halted

FDA accepts filing for DepoMorphine

Lumiracoxib approved by the MHRA for osteoarthritis and other indications

New CCR3 antagonist with oral activity in animal model of atopic dermatitis

3DP presents new orally active thrombin inhibitors at ACS meeting

Development of potent, selective cPLA2alpha inhibitors as antiinflammatory/analgesic agents

BMS discovers selective, orally active TACE inhibitors with antiinflammatory activity

RPR-749 is safe and lowers FFA levels in first human trial

Influenza virus neuraminidase inhibitor R-118958 and its active metabolite characterized by Sankyo

Good safety and PK profile emerges for CC-8490 in healthy volunteers

Tolvaptan preserves renal function in patients with congestive heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...